ABOUT US
Research has shown access to healthcare delivery can impact patients in many ways including delayed diagnosis and treatment, and inability to receive preventative care, which can lead to worse health outcomes. Our portfolio assets are focused on diagnosis and care delivery in neurology.
Our vision is to be a central resource for neurological screening, prevention, and care delivery. Our proprietary technology uses best in class artificial intelligence to power our suite of managed services, biomarker testing, and proprietary data dashboards.
Our BrainHealth platform is aimed to help patients with mild cognitive impairment or mild dementia. We educate patients on preventative neurology and the importance of lifestyle intervention. Our suite of services is focused on improving access to care regardless of where you live.
Strategic Vision
Leadership Team
Board of Directors
Science-based.
Always Learning.
Empowering.
Precise.
Groundbreaking.
We are
...a team of scientists, clinicians, entrepreneurs, and data scientists aiming to improve neurological outcomes for patients by improving access to prevention, diagnosis, and care delivery.
We partner with leading health systems, payors, national testing labs, and pharma companies to offer tech-enabled managed services, diagnostic biomarkers, clinical trial matching, faster access pathways to treatment, and digital therapeutic programs focused on improving neurological health and overall brain health.
Partners
NeuroVision shares common strategic, research, clinical and commercial goals with the broader academic and industry players focused on neurodegeneration, and has engaged in research and collaboration agreements and projects with many institutions and companies.
ACADEMIC
Research Agreements with 24 Academic Institutions
4 Novel Blood Biomarker License Agreements
Critical Antibody Supply and Research Agreement
INDUSTRY
Collaboration Agreements with 5 Pharmaceutical Companies
Investors
We are venture backed by individual and strategic investors who share our vision to transform neuroscience and access pathways for patients.
